TP53 and sarcoma: The P1-7R primers we used, were initially described by Bodmer’s group27,28 and have been widely used, including the Children Oncology Group study correlating TP53 mutations with sarcoma outcomes29, St Jude’s Children Hospital glioma study30 and several other studies31–35.